EVONILE PHARMA LIMITED

BSE: EVONILE500672ISIN INE234A01025

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹1,736.60+16.75 (+0.97%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,588.00
52W low: ₹750.00
Off 52W high: -32.90%
1M return: -11.70%
3M return: +6.36%
6M return: +65.28%
1Y return: +102.39%
20D avg volume: 2,963
50 DMA: ₹1,863.92
200 DMA: ₹1,354.36

Key ratios Standalone

Market cap: ₹4,288 Cr
Current price: ₹1,736.60
52W high / low: ₹2,588.00 / ₹750.00
Face value: ₹5.00
P/E: -1,071.98
P/B: 5.88
EPS (TTM): ₹-1.62
Book value / share: ₹295.34
ROE: -0.55%
ROCE: 15.70%
Operating margin: -164.75%
Net margin: -138.34%
Debt / equity: 0.00
Net debt: ₹-52.50 Cr
Interest cover: 103.90
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 36.8 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	56.05	103.81	90.55	85.90	90.33	87.55	83.88	93.00	87.10	92.29	81.17	84.54
	7.74	8.74	10.01	8.75	9.40	10.61	10.63	10.60	10.32	10.41	10.42	21.96
	63.79	112.55	100.56	94.65	99.73	98.16	94.51	103.60	97.42	102.70	91.59	106.50
	96.59	69.38	70.42	65.00	67.08	60.94	60.62	68.31	69.86	69.03	70.26	65.19
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	137.58	76.05	68.34	40.77	54.08	47.39	64.84	42.45	39.05	52.73	67.28	38.31
	14.35	4.72	4.35	6.14	5.30	5.29	3.17	4.81	5.20	5.54	5.11	6.30
	4.83	0.06	0.07	0.98	0.11	0.10	0.12	0.36	0.14	0.15	0.16	0.16
	3.89	0.42	0.42	0.48	0.52	0.53	0.53	0.53	0.58	0.55	0.14	0.26
	26.43	8.51	13.40	8.50	10.63	8.25	7.50	12.11	14.79	8.88	7.96	12.81
	-32.80	43.17	30.14	29.65	32.65	37.22	33.89	35.29	27.56	33.67	21.33	41.31
	-68.26	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	-101.06	43.17	30.14	29.65	32.65	37.22	33.89	35.29	27.56	33.67	21.33	41.31
	-23.52	10.96	4.89	13.56	8.43	9.60	4.59	9.84	7.15	7.94	6.65	14.74
	-77.54	32.21	25.25	16.09	24.22	27.62	29.30	25.45	20.41	25.73	14.68	26.57
	-31.41	13.05	10.23	6.52	9.81	11.19	11.87	10.31	8.27	10.42	5.95	10.76
Key metrics
	-92.34	43.65	30.63	31.11	33.28	37.85	34.54	36.18	28.28	34.37	21.63	41.73
	-164.70%	42.00%	33.80%	36.20%	36.80%	43.20%	41.20%	38.90%	32.50%	37.20%	26.60%	49.40%
	-138.30%	31.00%	27.90%	18.70%	26.80%	31.50%	34.90%	27.40%	23.40%	27.90%	18.10%	31.40%
	-9.00%	—	3.60%	—	4.10%	—	4.20%	—	—	—	—	—
	-37.90%	18.60%	8.00%	-7.60%	3.70%	-5.10%	3.30%	10.00%	—	—	—	—
	-420.10%	16.60%	-13.80%	-36.80%	18.70%	7.30%	99.60%	-4.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	336.31	354.33	356.27	335.07	378.74	399.87
	35.24	38.77	41.96	61.68	58.11	33.19
	371.55	393.10	398.23	396.75	436.85	433.06
	301.39	263.44	267.81	273.91	321.47	387.24
	0.00	0.00	0.00	—	—	—
	322.74	210.58	199.07	189.98	199.34	187.26
	29.56	21.08	18.72	22.96	35.64	101.89
	5.94	1.26	0.77	1.49	1.75	4.83
	5.21	1.95	2.19	2.61	6.06	9.65
	56.84	40.78	43.31	46.84	75.96	92.74
	70.16	129.66	130.42	122.84	115.38	45.82
	-68.26	0.00	0.00	—	—	-49.64
	1.90	129.66	130.42	122.84	115.38	-3.82
	5.89	36.48	29.52	37.65	12.02	0.10
	-3.99	93.18	100.90	85.19	103.36	-3.72
	-1.61	37.74	40.87	34.50	41.86	-1.51
Key metrics
	13.05	132.87	133.38	126.94	123.19	10.66
	3.88%	37.50%	37.40%	37.90%	32.50%	2.70%
	-1.19%	26.30%	28.30%	25.40%	27.30%	-0.90%
	—	15.70%	16.30%	—	—	—
	-5.20%	-0.50%	6.30%	-11.50%	-5.30%	—
	-103.74%	-7.70%	18.40%	-17.60%	2,878.50%	—
	—	46.39	74.57	—	—	—
	—	0.50	0.74	—	—	—
	—	0.00	0.00	—	—	—
	—	-52.50	-52.07	—	—	—
	—	36.8	30.5	—	—	—
Balance sheet
	—	978.27	947.81	—	—	—
	—	768.25	745.82	—	—	—
	—	52.50	52.07	—	—	—
	—	37.05	40.14	—	—	—
	—	53.32	41.11	—	—	—
	—	9.53	15.60	—	—	—
	—	2.88	4.54	—	—	—
	—	54.65	51.47	—	—	—
	—	144.97	142.05	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	817.83	784.96	—	—	—
Cash flow
	—	46.73	74.57	—	—	—
	—	17.63	-3.31	—	—	—
	—	-63.93	-64.15	—	—	—
	—	0.34	0.00	—	—	—

Compounded growth

Sales CAGR 3Y: -2.20%
Sales CAGR 5Y: —
Profit CAGR 3Y: -3.40%
Profit CAGR 5Y: —
Sales YoY (TTM): -5.20%
Profit YoY (TTM): -103.74%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 70.68%

Quarter	September 2026	June 2026
Promoter %	70.68%	70.68%

Holder	Type	Holding	Previous	Change
Waverise Investments Limited	Promoter	56.45%	56.45%	0.00%
Chryscapital Fund X	Promoter	10.32%	10.32%	0.00%
Two Infinity Partners	Promoter Group	3.91%	3.91%	0.00%
Atul Limited	Public	1.52%	1.52%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
EVONILE PHARMA LIMITED S	4,288	1,736.60	-1,071.98	15.70%	-5.20% TTM	-103.74% TTM	+102.39%

Filings & corporate actions

Recent announcements

Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026.4 Nov 2026 · Corp. Action / Record Date
Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 20264 Nov 2026 · Company Update / General
Intimation of the Newspaper publications made in Financial Express and Navshakti for the Financial Results pertaining to the quarter and half year ended September 30, 2026.4 Nov 2026 · Company Update / Newspaper Publication
Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026.4 Nov 2026 · Company Update / General
Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026.4 Nov 2026 · Result / Financial Results
Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026.3 Nov 2026 · Company Update / Press Release / Media Release
Submission of Investor Presentation for the Earnings Call scheduled on Wednesday, November 04, 2026.3 Nov 2026 · Company Update / Investor Presentation
Unaudited Financial Results for the Quarter and half year ended as on September 30, 20263 Nov 2026 · Result / Financial Results
Intimation of the Unaudited Financial Results along with the Limited Review Report for the Quarter and half year ended September 30, 20263 Nov 2026 · Board Meeting / Outcome of Board Meeting
Disclosure of the receipt of In-principle approval from the Stock Exchange i.e. BSE Limited in relation to the draft Letter of Offer.1 Nov 2026 · Company Update / General
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Letter of Offer and intimation ....1 Nov 2026 · Board Meeting / Board Meeting
Intimation of the Earnings call proposed to be held on November 04, 2026, at 02:30 PM IST26 Oct 2026 · Company Update / General
Intimation for the appointment of Mr. Gagan Sharma as the Senior Management Personnel of the Company.26 Oct 2026 · Company Update / Change in Management
Intimation of the Newspaper Advertisement made by the Company in Financial Express and Navshakti today i.e. October 14, 2026, w.r.t. the completion of dispatch of the Notice of Postal Ballot ....14 Oct 2026 · Company Update / Newspaper Publication
Intimation of the Notice of Postal Ballot (02/2026-27) dated October 08, 2026.13 Oct 2026 · AGM/EGM / Postal Ballot
Intimation of the certificate received from RTA in terms of Regulation 74(5) of the SEBI (Depositories and Participants Regulations), 2018.13 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Board of Directors of the Company Evonile Pharma Limited (formally known as Novartis India Limited) approved the raising of funds by way of Rights Issue at their Board Meeting held ....8 Oct 2026 · Company Update / Raising of Funds
The Board of Directors of Evonile Pharma Limited (formally known as Novartis India Limited) has approved the raising of funds by way of Rights Issue at their Board Meeting held today i.e. ....8 Oct 2026 · Company Update / Issue of Securities
Intimation of the Outcome of the Board Meeting held today dated October 08, 20268 Oct 2026 · Board Meeting / Outcome of Board Meeting
Intimation of the Credit Ratings assigned by CARE Ratings Limited.7 Oct 2026 · Company Update / Credit Rating
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/10/2026 ,inter alia, to consider and approve the raising of funds through ....5 Oct 2026 · Board Meeting / Board Meeting
Intimation regarding the Amendments to the Memorandum and Articles of Association of the Company1 Oct 2026 · Company Update / Amendments to Memorandum & Articles of Association
Intimation of the Change of Name of Company from Novartis India Limited to Evonile Pharma Limited pursuant to the Fresh Certificate of Incorporation dated October 01, 2026, issued by Ministry ....1 Oct 2026 · Company Update / Change of Name
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....30 Sep 2026 · Board Meeting / Board Meeting
Intimation of the closure of Trading Window30 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of the Voting Results and the Scrutinizers Report for the 78th Annual General Meeting of the Company held on Thursday, September 24, 2026.25 Sep 2026 · AGM/EGM / AGM
Intimation of the proceedings of the 78th Annual General Meeting of Novartis India Limited held on September 24, 2026.24 Sep 2026 · AGM/EGM / AGM
Intimation is hereby given that the Officials of the Company will be participating in the Conference / Meeting scheduled on Emerging India CEO Forum by Nuvama on Monday, September 28, 2026.23 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation regarding the newspaper publication made regarding the Corrigendum filed dated September 18, 2026, for the Notice of 78th Annual General Meeting21 Sep 2026 · Company Update / General
Corrigendum to the Notice of 78th Annual General Meeting dated August 27, 202618 Sep 2026 · AGM/EGM / AGM
Transcript of the Analysts / Institutional Investors Call held on September 11, 2026.15 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of the Audio Recording of the Investor / Analyst Call held on Friday, September 11, 2026.12 Sep 2026 · Company Update / Analyst / Investor Meet
With reference to the intimation of the Investor / Analyst Call dated September 08, 2026, please find attached herewith the Investor Presentation in relation to the same.11 Sep 2026 · Company Update / Investor Presentation
Intimation pursuant to Regulation 36(1)(b) of the SEBI LODR Regulations to non-email shareholders regarding the Weblink and Annual Report for FY 2025-26 by the way of physical dispatch of letters.9 Sep 2026 · Company Update / General
Intimation regarding the Investor / Analyst Call scheduled to be held on Friday, September 11, 2026, 04:00 PM IST onwards, through Physical and Virtual Mode.8 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation under Reg 30 of SEBI LODR regarding entering into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for its retina portfolio comprising ....8 Sep 2026 · Company Update / General
Intimation regarding the acquisition of trademarks "Minipress" and "Minipres" registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products ....7 Sep 2026 · Company Update / General
Newspaper Publication made on September 03, 2026, in Financial Express and Navshakti for the Intimation sent to the shareholders on September 02, 2026, regarding the Notice of the 78th ....3 Sep 2026 · Company Update / Newspaper Publication
Annual Report of Novartis India Limited for FY 2025-262 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 78th Annual General Meeting of Novartis India Limited to be held on Thursday, September 24, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM)2 Sep 2026 · AGM/EGM / AGM

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 25.0000	23 Jul 2025	23 Jul 2025	—
Final Dividend - Rs. - 25.0000	23 Jul 2024	—	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
23 Jul 2026 Board Meeting - Financial Results